The Endothelin Receptor Antagonist (ERA) market is a subset of the cardiovascular drug market. ERA drugs are used to treat a variety of cardiovascular conditions, including hypertension, pulmonary arterial hypertension, and congestive heart failure. These drugs work by blocking the action of endothelin, a hormone that can cause constriction of the blood vessels. This helps to reduce blood pressure and improve blood flow. ERA drugs are generally well-tolerated and have few side effects. The ERA market is highly competitive, with several major pharmaceutical companies offering products. These include Amgen, Bayer, Merck, Novartis, and Pfizer. Other companies, such as Actelion, Gilead, and United Therapeutics, also offer ERA drugs. These companies are continually researching and developing new drugs to improve the treatment of cardiovascular conditions. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
